Results 21 to 30 of about 31,287 (200)

Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a patient with sickle Cell Anemia

Clinical Medicine Insights: Oncology, 2012
We report a 41 year old male with sickle cell disease who developed a myelodysplastic syndrome and acute myeloid leukemia with complex karyotype involving chromosomes 5, 7 and 17 after 15 years of hydroxyurea treatment.
Walid Baz, Vesna Najfeld, Matthew Yotsuya, Jotica Talwar, Terenig Terjanian, Frank Forte   +5 more
doaj   +1 more source

Analysis of oxidative status and biochemical parameters in adult patients with sickle cell anemia treated with hydroxyurea, Ceará, Brazil

Revista Brasileira de Hematologia e Hemoterapia, 2011
BACKGROUND: Sickle cell anemia is a hemoglobinopathy caused by a mutation that results in the production of an abnormal hemoglobin molecule, hemoglobin S (Hb S).
Paulo Florentino Teixeira Neto, Romélia Pinheiro Gonçalves, Darcielle Bruna Dias Elias, Cleiton Pinheiro de Araújo, Hemerson Iury Ferreira Magalhães   +4 more
doaj   +1 more source

Differences in HRQOL among Children with SCD Who Received Hydroxyurea and Those Who Did Not: A Quantitative Comparison Study

Oman Medical Journal
Objectives: Hydroxyurea is been recommended for patients with sickle cell disease (SCD) as it reduces the complications from the disease by increasing the production of fetal hemoglobin.
Yusra Al Nasiri, Amal Al Sabahi, Karima Al Hanai, Mohammed Al Hanai, Shah Mohammed Wasifuddin, Nawal Al Mashayki, Mudhar Al Adawi, Kamla Al Nassri, Salah Al Awaidy   +8 more
doaj   +1 more source

“Intrapericardial Approach” for Venous Outflow Reconstruction in Living‐Donor Liver Transplantation for Budd‐Chiari Syndrome: Surgical Techniques and LongTerm Outcomes

Annals of Gastroenterological Surgery, EarlyView.
Unlike deceased‐donor liver transplantation, living‐donor liver transplantation (LDLT) for Budd‐Chiari Syndrome (BCS) presents distinctive challenges in hepatic venous (HV)‐outflow reconstruction because diseased HV–inferior vena cava (IVC) cannot be entirely replaced with healthy donor vessels.
Koichiro Hata, Tetsuya Tajima, Satoshi Ogiso, Shinji Uemoto, Etsuro Hatano   +4 more
wiley   +1 more source

Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial

JMIR Research Protocols, 2021
BackgroundSickle cell anemia (SCA) is a genetic blood disorder that puts children at a risk of serious medical complications, early morbidity and mortality, and high health care utilization.
Hood, Anna M, Strong, Heather, Nwankwo, Cara, Johnson, Yolanda, Peugh, James, Mara, Constance A, Shook, Lisa M, Brinkman, William B, Real, Francis J, Klein, Melissa D, Hackworth, Rogelle, Badawy, Sherif M, Thompson, Alexis A, Raphael, Jean L, Yates, Amber M, Smith-Whitley, Kim, King, Allison A, Calhoun, Cecelia, Creary, Susan E, Piccone, Connie M, Hildenbrand, Aimee K, Reader, Steven K, Neumayr, Lynne, Meier, Emily R, Sobota, Amy E, Rana, Sohail, Britto, Maria, Saving, Kay L, Treadwell, Marsha, Quinn, Charles T, Ware, Russell E, Crosby, Lori E   +31 more
doaj   +1 more source

Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial

American Journal of Hematology, EarlyView.
ABSTRACT Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard‐care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE‐1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard‐care to match sibling donor (MSD)‐HCT in ...
Francoise Bernaudin, Suzanne Verlhac, Elisabeth Ducros‐Miralles, Cécile Arnaud, Isabelle Genty, Marie Petras, Catherine Paillard, Gonzalo De Luna, Benoit Meunier, Isabelle Thuret, Annie Kamdem, Corinne Pondarré, Giovanna Cannas, Christelle Chantalat‐Auger, Nadia Firah, Sophie Pertuisel, Laure Joseph, Florence Missud, Mariane de Montalembert, Corinne Guitton, Claire Pluchart, Valentine Brousse, Monique Elmaleh, Vincent Gajdos, Emmanuella Leveillé, Ekaterina Belozertseva, Mabel Gaba, Catherine Poirot, Virginie Barraud‐Lange, Philippe Chadebech, France Pirenne, Myriam Bernaudin, Bénédicte Neven, Pierre Frange, Marie Angoso, Karima Yakouben, Bénédicte Bruno, Nathalie Dhédin, Jean‐Hugues Dalle, Regis Peffault Delatour, Camille Jung   +40 more
wiley   +1 more source

Iron Chelation Reduces DNA Damage in Sickle Cell Anemia

Clinical and Applied Thrombosis/Hemostasis, 2021
Sickle cell anemia (SCA) is a blood condition that causes severe pain. One of the therapeutic agents used for the treatment of SCA is hydroxyurea, which reduces the episodes of pain but causes DNA damage to white blood cells. The aim of this study was to
Rawan S. Al-Khateeb, Hanan S. Althagafy, Mohammad Zaki ElAssouli, Dunya A. Nori, Mohammed AlFattani, Salwa A. Al-Najjar, Turki Al Amri, Anwar M. Hashem, Steve Harakeh, Nawal Helmi   +9 more
doaj   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

Widespread Natural Occurrence of Hydroxyurea in Animals. [PDF]

PLoS ONE, 2015
Here we report the widespread natural occurrence of a known antibiotic and antineoplastic compound, hydroxyurea in animals from many taxonomic groups.
David I Fraser, Kyle T Liu, Bryan J Reid, Emily Hawkins, Andrew Sevier, Michelle Pyle, Jacob W Robinson, Pierre H R Ouellette, James S Ballantyne   +8 more
doaj   +1 more source

Nitric Oxide Mediation in Hydroxyurea and Nitric Oxide Metabolites’ Inhibition of Erythroid Progenitor Growth

Biomolecules, 2021
In several systems, hydroxyurea has been shown to trigger nitric oxide (NO) release or activation of NO synthase (NOS). To elucidate this duality in its pharmacological effects, during myelosuppression, we individually examined hydroxyurea’s (NO ...
Tijana Subotički, Olivera Mitrović Ajtić, Dragoslava Djikić, Marijana Kovačić, Juan F. Santibanez, Milica Tošić, Vladan P. Čokić   +6 more
doaj   +1 more source